First Parkinson’s gene therapy patient well after 1 year suggesting that the therapy is safe and effective

NewsGuard 100/100 Score

The first ever patient to have undergone gene therapy for Parkinson’s appears to have come through phase I without a hitch, suggesting that the therapy is safe and effective, reports Marina Murphy in Chemistry & Industry.

‘We have yet to analyse efficacy data, with the seventh of the planned twelve subjects only just having undergone gene transfer. . . But there have been no adverse effects related to the gene therapy so far,’ said lead researcher Matthew During, of the University of Auckland. He continues, ‘Our therapy is extremely safe and we hope there will be some symptomatic improvement.’

It is just over a year since the first patient, Nathan Klein, had a virus carrying a gene injected in a part of his brain. He claims to have experienced an improvement of 40–60% in overall symptoms when he is on his medication, and a 10–20% improvement when he is not. Prior to the surgery, he habitually suffered from a tremor on his right side.

Roger Barker, a Parkinson’s expert at the University of Cambridge, who was critical of the decision to go ahead with the trial, said the fact that there has been no adverse effects is good news, but because the patient is on low doses of his medication, it is not possible to determine whether the gene therapy is any better than a more aggressive drug regime, or subthalamic nucleus (STN) deep brain stimulation.

The treatment uses a harmless virus to introduce a gene into a part of the brain that is overactive in Parkinson’s patients, causing jerky movements. Introducing this gene leads to the production natural chemicals that inhibit the overactive brain cells. During’s group is the only one conducting human gene therapy trials in Parkinson’s and experts think that gene therapy is 20 years ahead of stem-cell therapy for Parkinson’s disease.

Phase II should start at the beginning of 2005.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers receive NIH grant to help develop gene therapy for HIV